June 16 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB PRESENTS FIRST DATA FROM THE MARGINAL ZONE LYMPHOMA COHORT OF THE TRANSCEND FL TRIAL DEMONSTRATING DEEP AND DURABLE RESPONSES WITH BREYANZI (LISOCABTAGENE MARALEUCEL)
BRISTOL-MYERS SQUIBB CO - 95.5% OF MZL PATIENTS TREATED WITH LISO-CEL ACHIEVED RESPONSE
Source text: ID:nBw5mdQ66a
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.